Article Sidebar
Published:
Nov 23, 2021Keywords:
prostate cancer biopsy ultrasound ciprofloxacin ceftriaxone infection
Article Details
Issue
Section
Articles
On acceptance, the copyright of a manuscript will be vested in the journal and publisher. Articles published in Afrimedic journal are distributed under the terms of the Creative Commons Attribution License which allows for unrestricted use, distribution and reproduction in any medium, for any non-commercial purpose, subject to proper citation of the original work.
References
1. Center MM, Jemal A, LortetTieulent J, Ward E, Ferlay J,
Brawley O, Bray F. International
variation in prostate cancer
incidence and mortality rate.
EurUrol 2012; 61:1079-1092.
2. Matthew R. Cooperberg, Joseph
C. PrestiJr, Katsuto Shinohara,
Peter R. Carroll. Neophlasm of the
prostate gland. Smith and
Tanagho’s General urology.
18thed. McGraw Hill . 2013; 350-
379
3. Osegbe DN. Prostate cancer in
Nigeria: facts and nonfacts. J.
Urol. 1997; 157(4): 1340-1343.
4. Jedy-Agba, E., Curado, M. P.,
Ogunbiyi, O., Oga, E., Fabowale,
T., Igbinoba, F., Osubor, G., Otu,
T., Kumai, H., & Koechlin, A.
(2012). Cancer incidence in
Nigeria: A report from
population-based cancer
registries. Cancer
Epidemiology, 36(5), 271-278.
5. Crawford ED, Haynes AL, Story
MW, Borden TA. Prevention of
urinary tract infections and sepsis
following transrectal prostate
biopsy. J Urol 1982; 127: 449-451
6. Fawcett DP, Eykyn S, Bultitude
MI. Urinary tract infections
following transrectal biopsy of the
prostate. South Med J 1974;
67:1453
7. Shittu OB, Kamara TB. Transrectal
biopsy of the prostate gland in
Ibadan. Nigerian Journal of
Surgical Research 2001; 3;3-4
8. Ojewola RW, Tijani KH, Jeje EA,
Ogunjimi MA, Anunobi CC,
Adesanya AO. An evaluation of
the usefulness of prostate specific
antigen and Digital rectal
examination in the diagnosis of
prostate cancer in an unscreened
population: An experience in a
Nigerian Teaching Hospital.
WAJM 2013; 32(1): 8-13
9. Mbaeri TU, Abiahu JA, Orakwe JC,
Oranusi CK, Nwofor AME, Obiesie
EA, Nwadi UV, Okoli CC.
Complications of prostate cancer
in two centers in Anambra state.
Orient Journal of medicine.2017;
29: 3-4
10. Agbugui JO, Obarisiagbon EO,
Osaigbovo EO, Osime CO,
Akumabor PN. Antibiotic
prophylaxis for transrectal
prostate biopsy: a comparison of
one day and five day rgimen.
Niger Postgraduate Med J 2014;
21(3): 213-217
11. Puig J, Darnell A, Bermudez P,
Malet A, Serrate G, Bare M, Prats
J. Transrectal ultrasound guided
prostate biopsy: is antibiotic
prophylaxis necessary? Eur.
Radiol. 2006; 16;939-943
12. Zani EL, Clark OA, Rodrigues
Netto N Jr. Antibiotic prophlaxis
for transrectal prostate biopsy.
Cochrane Database syst Rev.
2011, 11 (5) CD006576
13. Wolf JS, Bennett CJ, Dmochowski
RR, Hollenbeck BK, Pearle MS,
Schaeffer AJ, Pace KT. Best
practice policy statement on
urologic surgery antimicrobial
prophylaxis. J Urol. 2012; 180(5):
2262-2263
14. Williamson DA, Barrett LK, Rogers
BA, Freeman JT, Hadway P and
Paterson DL. Infectious
complication following transrectal
ultrasound-guided prostate
biopsy: New challenges in the era
of multi-drug resistant Escherichia
coli. Clinical infectious diseases
2013; 57(2): 267-274
15. Williamson DA, Roberts SA,
Paterson DL, Sidjabat H, Silvey A,
Masters j et al. Escherichia coli
blood-stream infection after
transrectal ultrasound-guided
prostate biopsy: implication of
fluoroquinolone resistant
sequence type 131 as a major
causative pathogen. Clin Infect
Dis 2012; 54: 1406-1412.
16. Rodriguez-Bano J, Picon E, Gijon
P, Harnendez JR, Ruiz M, Carmen
Pena et al.
a. Community-onset bacteremia
due to extended-spectrum betalactamase producing Escherichia
coli: risk factors and prognosis.
Clin Infect Dis 2010; 50: 40-48
17. Tumbarello M, Trecarichi EM,
Bassetti M, Guiseppe De Rosa F,
Spanu T, Di Meco E et al.
Identifying patients harbouring
extended-spectrum betalactamase
Enterobacteriaceae on hospital
admission: derivation and
validation of scoring system.
Antimicrob Agents Chemothera
2011; 55: 3485-3490
18. Aron M, Rajeev TP, Gupta NP.
Antibiotic prophylaxis for
transrectal needle biopsy of the
prostate: A randomized
controlled study. BJU Int.
2000;85:682-685
19. Fisher LD. Self-designing clinical
trials. Statistics in medicine.
1998;17:1151-1562
20. Obi AO and Nnodi IP. Low dose
Saddle Block anesthesia (with
1.5mg Bupivacane) for
Transrectal prostate biopsyExperience with 120 cases. J
AnesthClin Res 2014; 5(11):469-
452
21. Nwofor AME, Oranusi CK. Cancer
of the prostate at Nnewi,
Southeast, Nigeria. Nigeria
Journal of clinical practice. 2004;
7(2): 65-67
22. De Miranda BG, Cais DP, Moura
DNML, Martinez MC, Duarte
LDPG, Costa AM et al. Use of
ceftriaxone as prophylaxis for
transrectal ultrasound guided
prostate biopsy: A better choice
in a Quinolone-Resistance
Scenario?. Open Forum Infectious
Diseases. 2015; 2(1):1428
23. Wagenlehner FME, Van Oostrum
E, Tenke P, Tandogdu Z, Cek M,
Grabe M et al. infective
complication after prostate
biopsy: outcome of Global
prevalence study of infections in
urology 2010 and 2011, a
prospective multicenter prostate
biopsy study. Eur. Urol. 2013;
63(3): 521-527
24. Pinkhasov GI, Lin YK, Palmerola R,
Smith P, Mahon F, Kaag GM et al.
complications following prostate
needle biopsy requiring hospital
admissions or emergency visitsexperience from 1000
consecutive cases. Bju Int. 2012;
110(3): 369-374
25. Satyanarayana R, Parekh D.
Prevention and treatment of
biopsy related complications.
Current Urol Rep. 2014; 15(2):
381-388
26.Feliciano J, Teper E, Ferrandino M,
Machia RJ, Blank W, Grunberger I
et al. The incidence of
fluoroquinolone resistant
infections after prostate biopsy is
fluoroquinolone still effective
prophylaxis? J Urol. 2008; 179(3):
952-955
27.FO Ugwumba, II Nnabugwu, KN
Echetabu, AD Okoh, EI Udeh.
Rates and determinants of
complications following TransRectal Prostate Biopsy in Enugu,
Nigeria. JAMMR, 2017; 23 (10): 1-
8
Brawley O, Bray F. International
variation in prostate cancer
incidence and mortality rate.
EurUrol 2012; 61:1079-1092.
2. Matthew R. Cooperberg, Joseph
C. PrestiJr, Katsuto Shinohara,
Peter R. Carroll. Neophlasm of the
prostate gland. Smith and
Tanagho’s General urology.
18thed. McGraw Hill . 2013; 350-
379
3. Osegbe DN. Prostate cancer in
Nigeria: facts and nonfacts. J.
Urol. 1997; 157(4): 1340-1343.
4. Jedy-Agba, E., Curado, M. P.,
Ogunbiyi, O., Oga, E., Fabowale,
T., Igbinoba, F., Osubor, G., Otu,
T., Kumai, H., & Koechlin, A.
(2012). Cancer incidence in
Nigeria: A report from
population-based cancer
registries. Cancer
Epidemiology, 36(5), 271-278.
5. Crawford ED, Haynes AL, Story
MW, Borden TA. Prevention of
urinary tract infections and sepsis
following transrectal prostate
biopsy. J Urol 1982; 127: 449-451
6. Fawcett DP, Eykyn S, Bultitude
MI. Urinary tract infections
following transrectal biopsy of the
prostate. South Med J 1974;
67:1453
7. Shittu OB, Kamara TB. Transrectal
biopsy of the prostate gland in
Ibadan. Nigerian Journal of
Surgical Research 2001; 3;3-4
8. Ojewola RW, Tijani KH, Jeje EA,
Ogunjimi MA, Anunobi CC,
Adesanya AO. An evaluation of
the usefulness of prostate specific
antigen and Digital rectal
examination in the diagnosis of
prostate cancer in an unscreened
population: An experience in a
Nigerian Teaching Hospital.
WAJM 2013; 32(1): 8-13
9. Mbaeri TU, Abiahu JA, Orakwe JC,
Oranusi CK, Nwofor AME, Obiesie
EA, Nwadi UV, Okoli CC.
Complications of prostate cancer
in two centers in Anambra state.
Orient Journal of medicine.2017;
29: 3-4
10. Agbugui JO, Obarisiagbon EO,
Osaigbovo EO, Osime CO,
Akumabor PN. Antibiotic
prophylaxis for transrectal
prostate biopsy: a comparison of
one day and five day rgimen.
Niger Postgraduate Med J 2014;
21(3): 213-217
11. Puig J, Darnell A, Bermudez P,
Malet A, Serrate G, Bare M, Prats
J. Transrectal ultrasound guided
prostate biopsy: is antibiotic
prophylaxis necessary? Eur.
Radiol. 2006; 16;939-943
12. Zani EL, Clark OA, Rodrigues
Netto N Jr. Antibiotic prophlaxis
for transrectal prostate biopsy.
Cochrane Database syst Rev.
2011, 11 (5) CD006576
13. Wolf JS, Bennett CJ, Dmochowski
RR, Hollenbeck BK, Pearle MS,
Schaeffer AJ, Pace KT. Best
practice policy statement on
urologic surgery antimicrobial
prophylaxis. J Urol. 2012; 180(5):
2262-2263
14. Williamson DA, Barrett LK, Rogers
BA, Freeman JT, Hadway P and
Paterson DL. Infectious
complication following transrectal
ultrasound-guided prostate
biopsy: New challenges in the era
of multi-drug resistant Escherichia
coli. Clinical infectious diseases
2013; 57(2): 267-274
15. Williamson DA, Roberts SA,
Paterson DL, Sidjabat H, Silvey A,
Masters j et al. Escherichia coli
blood-stream infection after
transrectal ultrasound-guided
prostate biopsy: implication of
fluoroquinolone resistant
sequence type 131 as a major
causative pathogen. Clin Infect
Dis 2012; 54: 1406-1412.
16. Rodriguez-Bano J, Picon E, Gijon
P, Harnendez JR, Ruiz M, Carmen
Pena et al.
a. Community-onset bacteremia
due to extended-spectrum betalactamase producing Escherichia
coli: risk factors and prognosis.
Clin Infect Dis 2010; 50: 40-48
17. Tumbarello M, Trecarichi EM,
Bassetti M, Guiseppe De Rosa F,
Spanu T, Di Meco E et al.
Identifying patients harbouring
extended-spectrum betalactamase
Enterobacteriaceae on hospital
admission: derivation and
validation of scoring system.
Antimicrob Agents Chemothera
2011; 55: 3485-3490
18. Aron M, Rajeev TP, Gupta NP.
Antibiotic prophylaxis for
transrectal needle biopsy of the
prostate: A randomized
controlled study. BJU Int.
2000;85:682-685
19. Fisher LD. Self-designing clinical
trials. Statistics in medicine.
1998;17:1151-1562
20. Obi AO and Nnodi IP. Low dose
Saddle Block anesthesia (with
1.5mg Bupivacane) for
Transrectal prostate biopsyExperience with 120 cases. J
AnesthClin Res 2014; 5(11):469-
452
21. Nwofor AME, Oranusi CK. Cancer
of the prostate at Nnewi,
Southeast, Nigeria. Nigeria
Journal of clinical practice. 2004;
7(2): 65-67
22. De Miranda BG, Cais DP, Moura
DNML, Martinez MC, Duarte
LDPG, Costa AM et al. Use of
ceftriaxone as prophylaxis for
transrectal ultrasound guided
prostate biopsy: A better choice
in a Quinolone-Resistance
Scenario?. Open Forum Infectious
Diseases. 2015; 2(1):1428
23. Wagenlehner FME, Van Oostrum
E, Tenke P, Tandogdu Z, Cek M,
Grabe M et al. infective
complication after prostate
biopsy: outcome of Global
prevalence study of infections in
urology 2010 and 2011, a
prospective multicenter prostate
biopsy study. Eur. Urol. 2013;
63(3): 521-527
24. Pinkhasov GI, Lin YK, Palmerola R,
Smith P, Mahon F, Kaag GM et al.
complications following prostate
needle biopsy requiring hospital
admissions or emergency visitsexperience from 1000
consecutive cases. Bju Int. 2012;
110(3): 369-374
25. Satyanarayana R, Parekh D.
Prevention and treatment of
biopsy related complications.
Current Urol Rep. 2014; 15(2):
381-388
26.Feliciano J, Teper E, Ferrandino M,
Machia RJ, Blank W, Grunberger I
et al. The incidence of
fluoroquinolone resistant
infections after prostate biopsy is
fluoroquinolone still effective
prophylaxis? J Urol. 2008; 179(3):
952-955
27.FO Ugwumba, II Nnabugwu, KN
Echetabu, AD Okoh, EI Udeh.
Rates and determinants of
complications following TransRectal Prostate Biopsy in Enugu,
Nigeria. JAMMR, 2017; 23 (10): 1-
8
Main Article Content
Efficacy of single dose ciprofloxacin versus ceftriaxone in the prevention of prostate biopsy related infection.pdf
Abstract
Background: Prostate cancer is a major health concern world over, being the second most common neoplasm in men and the sixth commonest cause of cancer related death in the entire world. Trans-rectal ultrasound guided prostate biopsy is the gold standard technique for prostate cancer diagnosis. Prostate biopsy is associated with risk of urinary tract infection.
Objective: This study aims to compare efficacy of ciprofloxacin with that of ceftriaxone in reducing post-prostate biopsy infection.
